BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 25455883)

  • 1. Cost-effectiveness of PET and PET/computed tomography: a systematic review.
    Gerke O; Hermansson R; Hess S; Schifter S; Vach W; Høilund-Carlsen PF
    PET Clin; 2015 Jan; 10(1):105-24. PubMed ID: 25455883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of routine surveillance imaging of patients with diffuse large B-cell lymphoma in first remission.
    Huntington SF; Svoboda J; Doshi JA
    J Clin Oncol; 2015 May; 33(13):1467-74. PubMed ID: 25823735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis in the clinical management of patients with known or suspected lung cancer: [18F]fluorodeoxyglucose PET and CT comparison.
    Mansueto M; Grimaldi A; Torbica A; Pepe G; Giovacchini G; Messa C; Fazio F
    Q J Nucl Med Mol Imaging; 2007 Sep; 51(3):224-34. PubMed ID: 17538525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of 18F-FDG PET/CT in detecting suspected recurrence or metastasis in well-differentiated thyroid carcinoma patients with negative diagnostic total body scan in Thailand: a decision analysis.
    Khiewvan B; Nopmaneejumruslers C; Pusuwan P; Tuchinda P; Tojinda N; Ubolnuch K
    J Med Assoc Thai; 2013 Oct; 96(10):1350-64. PubMed ID: 24350419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of FDG-PET/CT for cytologically indeterminate thyroid nodules: a decision analytic approach.
    Vriens D; Adang EM; Netea-Maier RT; Smit JW; de Wilt JH; Oyen WJ; de Geus-Oei LF
    J Clin Endocrinol Metab; 2014 Sep; 99(9):3263-74. PubMed ID: 24873995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [18FDG-PET/CT cost-effectiveness compared to CT at the end of treatment in pediatric Hodgkin's lymphoma patients].
    García-Molina M; Chicaíza-Becerra L; Moreno-Calderon A; Prieto-Martínez V; Sarmiento-Urbina I; Linares-Ballesteros A
    Rev Salud Publica (Bogota); 2014; 16(2):260-9. PubMed ID: 25383499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic review of PET and PET/CT in oncology: a way to personalize cancer treatment in a cost-effective manner?
    Langer A
    BMC Health Serv Res; 2010 Oct; 10():283. PubMed ID: 20932288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PET-CT in oncological patients: analysis of informal care costs in cost-benefit assessment.
    Orlacchio A; Ciarrapico AM; Schillaci O; Chegai F; Tosti D; D'Alba F; Guazzaroni M; Simonetti G
    Radiol Med; 2014 Apr; 119(4):283-9. PubMed ID: 24277511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Analysis of cost-effectiveness in the diagnosis of fever of unknown origin and the role of (18)F-FDG PET-CT: a proposal of diagnostic algorithm].
    Becerra Nakayo EM; García Vicente AM; Soriano Castrejón AM; Mendoza Narváez JA; Talavera Rubio MP; Poblete García VM; Cordero García JM
    Rev Esp Med Nucl Imagen Mol; 2012; 31(4):178-86. PubMed ID: 23067686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of routine (18)F-FDG PET/CT in high-risk patients with gram-positive bacteremia.
    Vos FJ; Bleeker-Rovers CP; Kullberg BJ; Adang EM; Oyen WJ
    J Nucl Med; 2011 Nov; 52(11):1673-8. PubMed ID: 21984799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ¹⁸F-FDG PET/CT in inflammation of unknown origin: a cost-effectiveness pilot-study.
    Balink H; Tan SS; Veeger NJ; Holleman F; van Eck-Smit BL; Bennink RJ; Verberne HJ
    Eur J Nucl Med Mol Imaging; 2015 Aug; 42(9):1408-13. PubMed ID: 25655485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 18FDG-PET-CT in the follow-up of non-small cell lung cancer patients after radical radiotherapy with or without chemotherapy: an economic evaluation.
    van Loon J; Grutters JP; Wanders R; Boersma L; Dingemans AM; Bootsma G; Geraedts W; Pitz C; Simons J; Brans B; Snoep G; Hochstenbag M; Lambin P; De Ruysscher D
    Eur J Cancer; 2010 Jan; 46(1):110-9. PubMed ID: 19944595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective evaluation of the utility of 2-deoxy-2-[(18) F]fluoro-D-glucose positron emission tomography and computed tomography in staging locally advanced gastric cancer.
    Smyth E; Schöder H; Strong VE; Capanu M; Kelsen DP; Coit DG; Shah MA
    Cancer; 2012 Nov; 118(22):5481-8. PubMed ID: 22549558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of FDG PET-CT in the management of pulmonary metastases from malignant melanoma.
    Krug B; Crott R; Roch I; Lonneux M; Beguin C; Baurain JF; Pirson AS; Vander Borght T
    Acta Oncol; 2010; 49(2):192-200. PubMed ID: 20059314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cost-utility analysis of 18-fluoro-2-deoxyglucose positron emission tomography in the diagnosis of recurrent nasopharyngeal carcinoma.
    Yen RF; Yen MF; Hong RL; Tzen KY; Chien CR; Chen TH
    Acad Radiol; 2009 Jan; 16(1):54-60. PubMed ID: 19064212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of strategies introducing integrated ¹⁸F-FDG PET/CT into the mediastinal lymph node staging of non-small-cell lung cancer.
    Han Y; Xiao H; Zhou Z; Yuan M; Zeng Y; Wu H; Fang Y
    Nucl Med Commun; 2015 Mar; 36(3):234-41. PubMed ID: 25460305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of adding FDG-PET or CT to the diagnostic work-up of patients with stage III melanoma.
    Bastiaannet E; Uyl-de Groot CA; Brouwers AH; van der Jagt EJ; Hoekstra OS; Oyen W; Verzijlbergen F; van Ooijen B; Thompson JF; Hoekstra HJ
    Ann Surg; 2012 Apr; 255(4):771-6. PubMed ID: 22367443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Consistency of FDG-PET accuracy and cost-effectiveness in initial staging of patients with Hodgkin lymphoma across jurisdictions.
    Cerci JJ; Trindade E; Buccheri V; Fanti S; Coutinho AM; Zanoni L; Linardi CC; Celli M; Delbeke D; Pracchia LF; Pitela FA; Soares J; Zinzani PL; Meneghetti JC
    Clin Lymphoma Myeloma Leuk; 2011 Aug; 11(4):314-20. PubMed ID: 21816369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cost analysis of18F-FDG PET-CT from the perspective of the Brazilian Unified National Health System as healthcare provider: a study in a public healthcare center in Rio de Janeiro, Brazil].
    Caetano R; Schluckebier LF; Bastos CR; Silva RM; Carneiro MP; Silva JW; Biz AN
    Cad Saude Publica; 2014 Feb; 30(2):379-92. PubMed ID: 24627065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PET/CT in non-small cell lung cancer staging-promises and problems.
    Devaraj A; Cook GJ; Hansell DM
    Clin Radiol; 2007 Feb; 62(2):97-108. PubMed ID: 17207691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.